Home › Non-Small Cell Lung Cancer › Virginia › Charlottesville
Non-Small Cell Lung Cancer clinical trials in Charlottesville, VA
21 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Charlottesville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #66, Charlottesville
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
RecruitingPhase 2
- University of Virginia, Charlottesville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- UVA Comprehensive Cancer Center, Charlottesville
- UVA Health Fontaine Research Park, Charlottesville
- University of Virginia, Charlottesville
- and 1 more
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RecruitingPhase 3
- University of Virginia Health System, Charlottesville
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
RecruitingPhase 2
- University of Virginia Cancer Center, Charlottesville
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RecruitingPhase 2/3
- University of Virginia Health System, Charlottesville
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RecruitingPhase 3
- Clinical Study Site, Charlottesville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- University of Virginia Health System, Charlottesville
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
RecruitingPhase 1/2
- University of Virginia Cancer Center, Charlottesville
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RecruitingPhase 3
- Research Site, Charlottesville
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RecruitingPhase 3
- University of Virginia, Charlottesville
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
RecruitingPhase 2
- UVA Comprehensive Cancer Center, Charlottesville
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RecruitingPhase 2
- University of Virginia Cancer Center, Charlottesville
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2
- University of Virginia Cancer Center, Charlottesville
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
RecruitingPhase 2
- University of Virginia Health System, Charlottesville
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecruitingPhase 2/3
- University of Virginia Cancer Center, Charlottesville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
RecruitingPhase 1/2
- University of Virginia, Charlottesville
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
RecruitingPhase 2
- University of Virginia Health System, Charlottesville
GEMINI-NSCLC: NSCLC Biomarker Study
RecruitingObservational study
- University of Virginia, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Charlottesville
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of Virginia, Charlottesville
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY120 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH56 studies
- Washington, DC55 studies
Other studies in Charlottesville
- Acute Myeloid Leukemia16 studies
- Prostate Cancer15 studies
- Metastatic Cancer13 studies
- Endometrial Cancer13 studies
- Cancer (all types)13 studies
- Lung Cancer13 studies
- Heart Failure11 studies
- Ovarian Cancer10 studies
- Colorectal Cancer10 studies
- Type 1 Diabetes9 studies
- Breast Cancer9 studies
- Pancreatic Cancer9 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.